Sigma Planning Corp’s Rapport Therapeutics RAPP Stock Holding History

Sigma Planning Corp’s Portfolio RAPP Stock Details RAPP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1.01M	Buy	+30,000	New	+$1.3M	0.03%	582

Other funds holding RAPP

Catalyst Private Wealth San Mateo, California $239M AUM 21.76% 1-Year Est. Return

Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return

Sterling Capital Management Charlotte, North Carolina $4.92B AUM 24.73% 1-Year Est. Return

KBC Group Brussels, Belgium $47.9B AUM 37.61% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

SignatureFD Atlanta, Georgia $7.76B AUM 16.09% 1-Year Est. Return

MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return

True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return

Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return

Sigma Planning Corp's RAPP Position: Q3 2026 in Review

Sigma Planning Corp opened a new position in Rapport Therapeutics (RAPP) in Q3 2026: 30,000 shares worth $1.01M. The stake represents 0.03% of the portfolio and ranks #582 among its holdings.

16 funds tracked by Wall St. Rank hold RAPP as of Q3 2026.

Sigma Planning Corp held 30,000 shares of Rapport Therapeutics worth $1.01M as of Q3 2026.
Rapport Therapeutics was a new Sigma Planning Corp position in Q3 2026.
Rapport Therapeutics made up 0.03% of Sigma Planning Corp's portfolio in Q3 2026, its #582 holding.
16 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q3 2026.

Based on Sigma Planning Corp's 13F filing for Q3 2026, filed 23 Oct 2026.